UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
1-
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 18, 2024, Anavex Life Sciences Corp. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 56,307,974 shares of the Company’s Common Stock were present or represented by proxy at the Annual Meeting, representing approximately sixty-seven percent (67%) of the outstanding Common Stock as of April 26, 2024, the record date for the Annual Meeting.
At the Annual Meeting, four (4) proposals were submitted for a vote of the Company’s stockholders and the related results are as follows:
Proposal No. 1: The election of Christopher Missling, PhD, Jiong Ma, PhD, Claus van der Velden, PhD, Athanasios Skarpelos, Steffen Thomas, PhD and Peter Donhauser, D.O. for terms until the next succeeding annual meeting of stockholders or until such directors’ successor shall have been duly elected and qualified. The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy elected the six (6) directors by the following votes:
| Name | For | Withheld | Broker Non-Votes | |||||||||
| Christopher Missling, PhD | 30,256,642 | 3,637,351 | 22,413,981 | |||||||||
| Jiong Ma, PhD | 31,613,668 | 2,280,325 | 22,413,981 | |||||||||
| Claus van der Velden, PhD | 27,960,597 | 5,933,396 | 22,413,981 | |||||||||
| Athanasios Skarpelos | 31,049,785 | 2,844,208 | 22,413,981 | |||||||||
| Steffen Thomas, PhD | 31,421,534 | 2,472,459 | 22,413,981 | |||||||||
| Peter Donhauser, D.O. | 31,243,258 | 2,650,735 | 22,413,981 | |||||||||
Proposal No. 2: The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy ratified Grant Thornton LLP as the Company’s independent registered accounting firm by the following votes:
| For | Against | Abstain | ||||||||
| 54,408,426 | 1,275,036 | 624,512 | ||||||||
Proposal No. 3: The approval of a non-binding advisory resolution approving the compensation of the Company’s named executive officers, as described in the Company’s proxy statement. The stockholders approved the non-binding advisory resolution on executive compensation by the following votes:
| For | Against | Abstain | Broker Non-Votes | |||||||||||
| 28,406,111 | 4,728,255 | 759,625 | 22,413,983 | |||||||||||
Proposal No. 4: Stockholder proposal regarding shareholder opportunity to vote on excessive golden parachutes. The stockholders did not approve the shareholder proposal by the following votes:
| For | Against | Abstain | Broker Non-Votes | |||||||||||
| 13,199,210 | 18,454,499 | 2,240,280 | 22,413,985 | |||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANAVEX LIFE SCIENCES CORP. | |
| /s/ Christopher Missling | |
| Name: Christopher Missling, PhD | |
| Title: Chief Executive Officer | |
| Date: June 21, 2024 |